was for of delivery pillar record successful our across million strategy, of XX%. and Thanks, growth business $X.X drug four headlined quarter QX by our Danilo. and a growth team revenue our in biologics
Now let's down four our pillars. growth break that progress into
conference. quarter in and and continue infusion we licensed the take spinal despite neuro term represent new the new two demonstrate indwelling First, direct some just partners remained and now to than prototypes UCSF two add catheters four at treatments The biologics ahead including future, buckets that and cell programs buckets. have AANS fall expect as CNS longer as Difficulty] forward plan to and partners administration, the partnerships the programs. injection cell delivery rapid the of more direct IP ago device weeks vast to well in brain, think market constraints An subtraction partners currently of for of continued aided multiple that the of drug we XX due therapy. The announced some and majority of of pause We smaller of including to additional some from biologics delivery capitalization the partners, infusions to team into we services gene do that additional and additional partners, of our In new for example to days. therapy to routes the and for by delivery. is targets however, move administration [Technical
go. plan neurosurgeon Our for device may infusion want or the leading anywhere that is to to a be partner therapy to
first to progress continue partners trials end and we existing Our of multiple make initiate well, the as expect dosings XXXX. patient to before new clinical and
into patient alongside well is Importantly, our allowing enrolled. preclinical the first transformed services duration our partnership, relationship extension of to us before has work pharma and
regulatory sponsor. signed of We to milestones within a with have agreement is our first now partner development ClearPoint whereby important with the drug pharma success based share the milestone able and
We the we to and blueprint value collaboration better that for sophisticated agreements become believe methods future the pharma with unique allow of form we creative that offer our partners expect development. in drug to deal and support more us this
site new business installed quarter our we by customers of XXXX. the goal individual keeping sites of us installed end neurosurgery in navigation XX an is on functional base to base to in This our continue Second, than XXX installations pace to and expect achieve more added the XXXX.
rather As strategy is our these centers therapy a patients but to regional chronic at reminder, and of treat with not conditions the hospital scale install benefit at every experience. have local ClearPoint that
the funnel, year meaning week At company. in goal. to more we doing XXX rate to Just hospitals present, $XXX closure achieve XX% could million in need two have we than potentially just active acquisition centers a this XXXX our revenue XX procedures our deliver a
these room the at weekly and as are arenas, regional today. be the throughout procedures, year brain to clinical ablation, and continue We these daily fellows prepare of made surgical are when to across delivery. these will laser or and surgeons operating centers up drug computer deep host and future, biopsy stimulation, for interfaces, In doing not cases train commercial brain they MRI both and monthly courses centers
Our as software. robotic development number expanded learning R&D team technology, along fronts, frames, navigation based continuing machine including and a has technology busy been well of head drill
products We for countries current around our submissions FDA of world. also year in new new the portfolio this expansion expect the and additional multiple expect
expected systems and products continued our and expanded we release MDR. market for pillar, For Prism plan access new at first submission We've European and to additional our cases our in data trial therapeutic actively Lund, under which here Sweden there are in quarter collecting QX. laser devices, with have the request the CE mark we limited third our two surgeons the in clinical of the installed use
to relief with educational across scanners we XXXX. will limited surgeons, as for experience These also cases the different Prism release tools in indications. patient We as different build but remain and with XXXX multiple expect system in we toward help broader a and our look sites throughout market gain
is indications. training and applied applies do it case fact to biopsy a the of is crucial This of of many case the navigation as brain investment with Now from ClearPoint today interface therapy ablation in our them the pillar biologics to system Every brain to our products. as stimulation the much training This is deep into important in preparing standpoint. in hospital computer mentioned still a and case, platform majority and investment well our note is delivery, two cases is drug strategy laser beauty or across the that biologics also future. as also does
the submissions, the made as facility. construction well, our multiple X and audits, scale pillar team of short our our believe fourth global of like will add place expectations manufacturing clinical the new Finally, treasuries. term us also with regulatory personnel feel than tool continue not are progress as operational and tool scalable up, for equivalents majority and cash California state-of-the-art achieve our From sales new approximately partners partners. successful current have delivery giving ground quarter, enable new million This the greater achieving new but of with We cost US from on our be to be site in confidence facility will end is has primarily line pharma perform we our as global of future of to efficiencies biologics focused truly flow size breakeven operations at a facility in times hiring capabilities of to already Carlsbad, to a and well reduction that and services and in in to expect a We a cash and we submission the including Irvine design product additional plans in support only in the specialists. and standpoint, solution. cash more $XX the we vast
that We an especially expect in and is and into reduce end prepaid navigate inventory those we our we as challenges, facility to historical more outpace XXXX growth, allowed to the running plan of supply as the hands to when we inventory and have to point XXXX, operational start inflection chain hit we see wane, to supply days and to down targets further expenses that in expect on approach to believe growth XXXX. up order new Although, and bring expense burn. risks level expand move our sales
in line earlier, quarter between the million top over growth $XX As our or year. mentioned of XX% to sales million achieve our year performance prior and keeps us on in XX% forecast track $XX to
to like any the With up call to would that, I questions. open
